Mucinex® for Treatment of Filamentary Keratitis

Mass Eye and Ear

Status: Completed

Conditions: Filamentary Keratitis

Treatments: Drug: Mucinex®

Study type: Interventional

Funder types: Other

Identifiers

NCT02859246

16-044H

Details and patient eligibility

About

It is a pilot study aimed to determine if oral Mucinex® is effective in reducing the amount of corneal filaments and improving symptomology in subjects with filamentary keratitis.

Full description

The study is aimed to determine if oral administration of Mucinex® is effective in reducing the amount of corneal filaments and improving symptomology in subjects with filamentary keratitis. Subjects will be instructed to take 600 mg tablets of extended release Mucinex® twice a day (total dose is 1.2 g/day) for 4 weeks.

Enrollment: 15 patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with filamentary keratitis
• 18 years and older

Exclusion criteria

• Active ocular surface infection of any type
• Recent ocular surgery (<30 days) history of nephrolithiasis as Mucinex® has been associated in rare cases of development of kidney stones
• Schirmer's test<3mm
• History of hypersensitivity to Mucinex®
• Concurrent eye disease requiring immediate initiation of a new treatment (e.g. topical steroids) restriction for water intake can exacerbate the risk of nephrolithiasis.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

15 participants in 1 patient group

Mucinex

Other group

Description:

600 mg of Mucinex 2 times a day.

Treatment:

Drug: Mucinex®